|
Stratification covariate
|
No. of patients
|
Underweight (HRa)
|
Normal weight [HR (95% CI)a]
|
Overweight/obese [HR (95% CI)a]
|
P
b
|
|---|
|
Age (years)
|
0.675
|
|
<45
|
419
|
1.0
|
1.01 (0.74–1.38)
|
0.74 (0.50–1.09)
| |
|
≥45
|
400
|
1.0
|
0.76 (0.55–1.06)
|
0.54 (0.37–0.79)
| |
|
Sex
|
0.680
|
|
Men
|
681
|
1.0
|
0.82 (0.64–1.04)
|
0.59 (0.44–0.79)
| |
|
Women
|
138
|
1.0
|
1.29 (0.67–2.45)
|
0.93 (0.45–1.94)
| |
|
UICC T category
|
0.471
|
|
T1–2
|
369
|
1.0
|
0.84 (0.60–1.17)
|
0.78 (0.52–1.17)
| |
|
T3–4
|
450
|
1.0
|
0.88 (0.65–1.19)
|
0.49 (0.34–0.70)
| |
|
UICC N category
|
0.501
|
|
N0–1
|
417
|
1.0
|
0.83 (0.61–1.14)
|
0.55 (0.37–0.82)
| |
|
N2–3
|
402
|
1.0
|
0.86 (0.60–1.18)
|
0.67 (0.46–0.98)
| |
|
Metastasis onset
|
0.551
|
|
Synchronous
|
272
|
1.0
|
0.94 (0.60–1.49)
|
0.55 (0.33–0.90)
| |
|
Metachronous
|
547
|
1.0
|
0.80 (0.62–1.04)
|
0.67 (0.48–0.92)
| |
|
Lung metastasis
|
0.761
|
|
Absent
|
469
|
1.0
|
0.92 (0.69–1.24)
|
0.66 (0.46–0.95)
| |
|
Present
|
350
|
1.0
|
0.78 (0.54–1.12)
|
0.62 (0.40–0.94)
| |
|
Liver metastasis
|
0.098
|
|
Absent
|
574
|
1.0
|
0.70 (0.54–0.91)
|
0.45 (0.32–0.62)
| |
|
Present
|
245
|
1.0
|
1.39 (0.22–2.19)
|
1.46 (0.88–2.43)
| |
|
Bone metastasis
|
0.051
|
|
Absent
|
382
|
1.0
|
0.83 (0.58–1.18)
|
0.76 (0.50–1.14)
| |
|
Present
|
437
|
1.0
|
0.91 (0.68–1.23)
|
0.57 (0.39–0.82)
| |
|
Solitary lesion
|
0.062
|
|
No
|
701
|
1.0
|
0.90 (0.72–1.14)
|
0.60 (0.45–0.80)
| |
|
Yes
|
118
|
1.0
|
0.35 (0.14–0.86)
|
0.44 (0.17–1.13)
| |
|
Number of involved sites
|
0.331
|
|
One
|
545
|
1.0
|
0.72 (0.57–0.99)
|
0.53 (0.38–0.74)
| |
|
Two or more
|
274
|
1.0
|
1.11 (0.75–1.66)
|
0.84 (0.52–1.33)
| |
|
Treatment modality
|
0.055
|
|
CT
|
607
|
1.0
|
0.92 (0.71–1.19)
|
0.56 (0.41–0.77)
| |
|
CT + LT
|
212
|
1.0
|
0.74 (0.46–1.21)
|
0.89 (0.52–1.52)
| |
-
OS overall survival; BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval
-
aAdjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved sites, and treatment modality, excluding stratification covariate
-
b
P for interaction
